Wednesday March 11Wednesday, 11 March 2026 - PT (Pacific Time, GMT-08:00)

To address the growing demand for AstraZeneca’s medicines, we have been developing intensified cell culture processes to boost productivity and efficiency in drug substance manufacturing. Central to these efforts is the implementation of a perfusion seed vessel to increase the initial cell mass in the production bioreactor as well as optimizing the feed composition and feed strategy in the Fed Batch production stage. These combined strategies have resulted in substantially higher productivity across a diverse range of molecules and modalities, while consistently maintaining product quality and have been instrumental in establishing AstraZeneca’s Intensified Fed Batch platform process.

NIST reference materials for the biomanufacturing and biopharmaceutical industries.

In the last several years NIST has developed a number of reference materials (RMs) geared toward the biopharmaceutical industry. These include the NISTmAb, an NS0-produced IgG1k, the NISTCHO, a CHO cell line expressing the amino acid sequences of the NISTmAb, and the cNISTmAb, the product of the NISTCHO. All three RM materials are open access with minimal IP constraints to encourage open innovation and pre-competitive research. The properties of the RMs will be presented along with examples of how the community uses these materials.

A visionary panel on trends shaping the future: decentralized production, autonomous operations, evolving supply chains, and end-to-end continuous processes. Panelists will explore how digital and AI-enabled systems will define the next decade.